Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Everest Approved to Start China Trials of Kidney Inflammation Therapy

publication date: Dec 19, 2019

Everest Medicines, a US-China biopharma formed by C-Bridge, was approved to start China trials of Nefecon, a novel oral formulation of the corticosteroid budesonide aimed at treating IgA Nephropathy, a chronic autoimmune kidney disease. Everest in-licensed greater China rights to Nefecon from Sweden's Calliditas Therapeutics earlier this year in a $121 million agreement. In Sweden, Calliditas has completed a successful Phase IIb trial of Nefecon in patients with inflammatory kidney disease. Everest paid $15 million upfront; the China trial approval triggers a $5 million milestone payment to Calliditas. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital